- Kewaunee Scientific Corporation reported **sales of $240.5 million** for fiscal year 2025, an **18.0% increase** compared to **$203.8 million** in the prior year.  **[55529_0001193125-25-189068_d55511dex992.htm:1]** **[55529_0001193125-25-189068_d55511dex991.htm:2]** 
- The company's diluted earnings per share for fiscal year 2025 were **$3.83**, compared to **$6.38** in the prior fiscal year, while adjusted diluted earnings per share increased to **$5.37** from **$4.19**.  **[55529_0001193125-25-189068_d55511dex992.htm:1]** **[55529_0001193125-25-189068_d55511dex991.htm:2]** **[55529_0001193125-25-189068_d55511dex991.htm:3]** 
- Kewaunee successfully completed the acquisition of **Nu Aire, Inc.** on **November 1, 2024**, which expanded its product offerings and market presence.  **[55529_0001193125-25-189068_d55511dex992.htm:1]** **[55529_0001193125-25-189068_d55511dex992.htm:2]** 
- The company's order backlog was **$214.6 million** on **April 30, 2025**, an increase from **$155.6 million** on **April 30, 2024**.  **[55529_0001193125-25-189068_d55511dex992.htm:1]**

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU)